Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):158–162. doi: 10.1097/QAI.0000000000002005

Table 1:

Characteristics of the Sample and Predictors of Non-Retention in Cox-Proportional Hazards Models

Overall %
N=294		 Unadjusted HR:
95% CI		 DBS FTC-TP
Model
AHR: 95% CI		 DBS TFV-DP
Model
AHR: 95% CI
Age at study entry, median (IQR)1 33 (27-42) 0.79: 0.66-0.962 0.90: 0.71-1.152 0.82: 0.64-1.042
Race: White 45 Ref. Ref. Ref.
   Asian 5 1.31: 0.56-3.05 1.42: 0.52-3.87 1.91: 0.71-5.12
   Black 13 1.73: 0.93-3.25 1.09: 0.49-2.44 0.89: 0.39-2.02
   Latino 32 1.78: 1.21-2.63 1.29: 0.65-2.53 1.36: 0.69-2.67
   Mixed/other 4 0.94: 0.34-2.60 1.62: 0.55-4.80 1.41: 0.48-4.20
Transwoman (vs. MSM) 3 1.12: 0.28-4.54 0.87: 0.20-3.67 0.99: 0.24-4.11
Site:  San Francisco 36 Ref. Ref. Ref.
   Miami 31 2.37: 1.63-3.45 1.13: 0.59-2.18 1.15: 0.59-2.23
   Washington D.C. 32 0.92: 0.52-1.58 0.73: 0.38-1.40 0.78: 0.41-1.51
Sub-optimal adherence by TFV-DP (<700 fmol/punch) at any visit3 292 4.21: 2.57-6.903 - 4.31: 2.43-7.623
Undetectable DBS FTC-TP at any visit3 252 7.53: 4.81-11.783 6.27: 3.83-10.223 -

AHR: Adjusted hazard ratio; DBS: Dried Blood Spot; FTC-TP: emtricitabine-triphosphate; TFV-DP: tenofovir-diphosphate; CI: Confidence interval; IQR: inter-quartile range; MSM: Men who have sex with men.

1

Scaled per ten years

2

Lowest documented adherence during course of the demo project

3

Treated as a time-dependent covariate in survival analysis